UK markets close in 8 hours 5 minutes

Bone Biologics Corporation (BBLG)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2280-0.0095 (-4.00%)
At close: 04:00PM EDT
0.2380 +0.01 (+4.39%)
After hours: 07:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.2375
Open0.2277
Bid0.0000 x 800
Ask0.0000 x 900
Day's range0.2277 - 0.2381
52-week range0.1780 - 3.1900
Volume20,017
Avg. volume196,001
Market cap3.489M
Beta (5Y monthly)0.48
PE ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.90
  • Business Wire

    Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization

    BURLINGTON, Mass., January 26, 2023--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has engaged Avania as the contract research organization (CRO) for the Company’s pilot clinical trial with NB1. Avania is an integrated global, full-service CRO with specialized expertise in medical devices, novel technology and drug-device combination products. The trial will evaluate the safety and effectiveness of Bone Biologic’s novel NB

  • Business Wire

    Bone Biologics CEO Issues Letter to Stockholders

    BURLINGTON, Mass., October 25, 2022--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Jeffrey Frelick.

  • Business Wire

    Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering

    BURLINGTON, Mass., October 12, 2022--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced underwritten public offering of units of securities for total gross proceeds of $5,100,000, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company plans to use the net proceeds to fund its planned clinical trials, maintain and extend its patent por